This general paper starts with principles that are obvious to those who already know about biological standardization.
The third is that there is true randomness in the treatment of variables in the method of comparison.
Finally, the assay should be constructed on a proper biometric basis (e.g., of parallel line assays) and the assay result should provide its own internal evidence of validity.
Take the first assumption, for example: that like is being compared to like. One sample of a pure chemical substance (i.e., one that can be completely characterized by chemical and physical means) should be comparable to another; but for a substance that cannot be defined by chemical and physical methods, any two preparations of it may differ in an unknown way and to an uncertain extent. Standardization then requires that each such comparison material be related quantitatively to another, and ultimately to one single common one. This criterion of similarity is deceptively simple, but competitive binding assays require that it be followed most rigorously.
Binding assays depend on the avidity of union between the binding sites on the binding protein (antibody or other receptor) and on one or more configurations on the surface of the substance bound. The energy of the bonds involved depends on the spatial closeness of fit and the nature of the binding forces between the substance bound and the binding protein. In practice, this means that a working standard must be calibrated in terms of the primary standard in the whole assay system in which it is to be used. The corollary of this is that the potency assigned to a secondary standard calibrated in one system (which may be highly specific) will not be correct in any other system of different degree of specificity. With any change of any component of the assay system each working standard should, therefore, be recalibrated with the same primary standard.
These statements require some mental assimilation, but they do profoundly affect the selection of a suitable material to use as a working standard and how the standard should be prepared. One most important de- The primary standard should be one for which there is a consensus of experts and should have recognized official status. A brief account of the steps taken to set up WHO international biological standards will give you an idea of how this is done.
Responsibility for setting up international standards for hormones (as well as antibiotics, enzymes, and blood products) was vested with the Division of Biological Standards at the National Institute for Medical Research (Mill Hill, London) until it was transferred to the National Institute for Biological Standards and Control that was created in 1972. The material itself may come from any of the sources mentioned above. It usually consists of a "large" (always a relative term) amount of material. (It may be several grams of, e.g., human choriogonadotropin or half a milligram of human parathyrin). Generally, and preferably, it is highly purified, but sometimes an impure preparation is chosen if that is more stable. it is then tested for substances that might interfere in assays, and tests are done to ensure that the activity is retained after a sample has been freeze-dried. Arrhenius plot. The data confirmed that the loss of biological activity in this preparation followed a first-'order reaction, and that at -20 #{176}C in the dark, a loss of 1% activity could be expected in about a quarter of a century.
This remarkable stability (which is, incidentally, not unusual for an international standard) is believed to be attributable to the absence of contaminating enzymes.
The second aspect of stability is with respect to the There is likely to be a discontinuity of assay results with each change of a standard; such discontinuity would be reduced in frequency and magnitude if the number of different working standards was kept to a minimum. Another improvement would be to make sufficient quantities of such standards to last several years, so that discontinuity occurred as infrequently as possible.
Fifteen years ago the standardization of corticotropin was an acute problem, because the relative potencies of batches in subcutaneous and intravenous assays differed unpredictably by several fold. That problem was tackled by making enough of an international working standard so that everyone who wanted to assay corticotropin could have an ampoule; about 45 000 such ampoules have been distributed during the last 15 years.
These are some of the logistical problems of providing biological standards. Another aspect of standardization is the way in which the results of assays should be expressed.
We all find it difficult to agree whether they are best stated in terms of mass, or molarity, or in immunoassay units defined by an International Reference Preparation. and lutropin, and human renin. Because the need for these international reference materials was so urgent, the evidence on which they were deemed suitable does not always include results from an extensive study.
The fourth section of the Report is an outline description of how a national hormone immunoassay service could be set up, because there is already intense interest in many countries in a service such as that which exists in England.
It also recommends a scheme for the complementary and entirely different function of monitoring laboratory performance on coded quality-control plasmas organized on a national basis. What does all this amount to? I hope you can appreciate the immense international collaboration that goes into setting up WHO standards, and why this can sometimes be slow. It will be a huge effort and responsibility for national regulatory agencies to set up national standards and to introduce quality control. Obviously it will take time to implement these recommendations. There will be great difficulty in sorting out priorities, and I am sure each of you will find that it is always other people's priorities that are so infinitely odd. Obviously the top priorities will have to be reserved for the most widely used assays: for those used for screening and for those that are most important in clinical medicine.
But for this rapidly developing technology, it is unremitting research that must keep standardization and standards practical and appropriate.
